Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA component of 7SK nuclear ribonucleoprotein (RN7SK)
- Target
- RN7SK
- Molecular classification
- Small nuclear RNA (snRNA), Non-coding RNA, Ribonucleoprotein complex component
01
Overview
The RNA component of 7SK nuclear ribonucleoprotein (RN7SK, commonly "7SK") is a highly abundant, non-coding small nuclear RNA present in metazoan cells. It forms a ribonucleoprotein complex (7SK snRNP) with core proteins including HEXIM1/2, LARP7, MePCE, and P-TEFb (CDK9/CyclinT1). 7SK RNA regulates transcription by sequestering and inactivating P-TEFb, a major RNA polymerase II kinase, thus inhibiting transcription elongation. The complex undergoes conformational changes depending on protein interactions and cellular signals. Dysregulation of RN7SK or associated proteins is linked to various diseases such as cancer, cardiovascular conditions, and viral infections. Despite its essential role in transcription regulation, RN7SK is not directly targeted by approved drugs. Its regulatory network is a subject of intense study due to its central role in controlling gene expression and cell fate.
- Other names
- 7SK RNARN7SK7SK snRNA7SK nuclear RNA
02
Mechanism of action
Not applicable for direct drugs; however, modulation of the RN7SK pathway (mainly through P-TEFb release or inhibition) can alter global transcription elongation.
03
Biological functions
Regulation of transcription elongation by sequestration and inhibition of positive transcription elongation factor b (P-TEFb)Scaffold for snRNP assemblyRNA-mediated control of gene expressionCellular homeostasis (via control of RNA polymerase II activity)
04
Disease associations
Cancer (dysregulation linked to oncogenesis, especially through altered P-TEFb activity)Heart diseaseDevelopmental disordersViral infection (notably HIV transcriptional regulation)
05
Safety considerations
None specific for RN7SK, as it is not a drug target. Disruption of RN7SK function can lead to broad, pleiotropic changes in gene expression and cellular homeostasis. Therapeutic challenges would relate to targeting protein components of the complex, not RN7SK itself.
06
Interacting drugs
None directly; no small-molecule drugs are known to target RN7SK or its RNA directly as of current research. Indirectly, some experimental approaches consider targeting components of the 7SK snRNP (e.g., P-TEFb inhibitors) in cancer, but not the RNA itself.
07
Biomarkers
None established; the expression or integrity of the RN7SK-7SK snRNP complex is sometimes studied as a marker of transcriptional activity in cancer and viral infection research
Beyond the preview
Go deeper on RNA component of 7SK nuclear ribonucleoprotein (RN7SK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RNA component of 7SK nuclear ribonucleoprotein (RN7SK).